AlphaMadera's AlphaVal page computes Bio-Techne Corporation's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag TECH as undervalued, fairly valued, or overvalued.

What is Bio-Techne Corporation's fair value?

Fair value for TECH is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value TECH?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from TECH's most recent reported fundamentals.

TECH - Bio-Techne Corporation

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $66.44 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 80% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Overvalued Strong

Trading 101.8% above fair value

Current Price $72.12

Bear Case $27.47 61.9% downside ($27.47 - $72.12) / $72.12 = -61.9% 5% stage 1 growth, 11% discount

Fair Value $35.73 50.5% downside ($35.73 - $72.12) / $72.12 = -50.5% 8% stage 1 growth, 11% discount

Bull Case $43.47 39.7% downside ($43.47 - $72.12) / $72.12 = -39.7% 11% stage 1 growth, 11% discount

Adjust Assumptions

DCF Stage 1 Growth Rate

8.2%

Discount Rate (WACC)

11.0%

Terminal Growth Rate

3.0%

Key Value Driver

FCF growth rate (8% base case)

Terminal Value % of EV 37%

Implied Market Multiple 51.2x

Market is pricing in (growth) 21.5% vs our 8.2% base

Plain-Language Summary

Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $66.44 from 26 analysts, using a 25% weight on analyst consensus. That produces an estimated intrinsic value of $35.73 per share.

Warnings

⚠ Stock-based employee pay equals 56% of profits. This dilutes existing shareholders, so cash flow alone overstates what owners really earn.

ℹ Wall Street's average price target is $66.44 (from 26 analysts). Our estimate is 62% below the consensus -- consider that gap carefully.

Key Risks

P/E alone misleads — earnings depressed by growth investment
Cyclical or commodity businesses may be misclassified as platforms
Terminal value dominance suggests sensitivity to long-run assumptions